Journals / SDÜ Tıp Fakültesi Dergisi / 2022 / Cilt: 29 - Sayı: 4

EARLY PREDICTORS OF SEVERE DISABILITY IN GUILLAIN–BARRÉ SYNDROME

GUİLLAİN-BARRÉ SENDROMUNDA AĞIR ÖZÜRLÜLÜĞÜN ERKEN BELİRTEÇLERİ

Pages
643–649
Publication Date
2022-12-27
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion We identified multiple characteristics that can predict severe disability in GBS patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective Guillain-Barré syndrome (GBS) is an autoimmune neurological disorder with non-negligible morbidity and mortality.
📊
Key Findings & Data:Material and Method We retrospectively reviewed the medical records of 121 patients diagnosed with GBS between January 1, 2018, and December 31, 2021.
💡
Conclusion & Impact:Conclusion We identified multiple characteristics that can predict severe disability in GBS patients.
🔬Design:Review & Systematic Survey
📍Scope:2018 Verileri
⚙️Variables:Biyobelirteçler · Guillain-Barré disabilite skoru · Guillain-Barré sendromu

Abstract

Objective Guillain-Barré syndrome (GBS) is an autoimmune neurological disorder with non-negligible morbidity and mortality. This study aimed to evaluate different patient characteristics and laboratory findings as early predictors of severe disability in GBS patients. Material and Method We retrospectively reviewed the medical records of 121 patients diagnosed with GBS between January 1, 2018, and December 31, 2021. Data regarding demographic characteristics, presenting complaints, co-morbidities, previous infection history, neurological examination findings, GBS Disability Scores (GDS) on the 1st day and by the end of the first month, laboratory parameters of serological and cerebrospinal fluid (CSF) examination, electromyoneurography results, GBS subtypes, treatments, treatment-related complications, and prognoses were recorded. Results The median age of the 121 patients was 58 (20–87) years (n = 73 males, 60%). The average GDS was 3 on admission and 2 at the end of the first month. The serum C-reactive protein (CRP) and CSF protein levels were raised, while vitamin D levels were reduced. Advanced age, cranial nerve involvement, history of infection, admission to the intensive care unit (ICU), need for mechanical ventilation (MV), presence of complications, high plasma CRP levels, neutrophil-lymphocyte ratio (NLR), and plateletlymphocyte ratio (PLO) were significantly associated with severe disability in GBS patients at day 1 and at the end of the first month. Conclusion We identified multiple characteristics that can predict severe disability in GBS patients.

Özet

Amaç Guillain-Barré sendromu (GBS), ihmal edilemez morbidite ve mortaliteye sahip otoimmün nörolojik bir hastalıktır. Bu çalışma, GBS hastalarında ağır engelliliğin erken belirteçleri olarak farklı hasta özelliklerini ve laboratuvar bulgularını değerlendirmeyi amaçladı. Gereç ve Yöntem 1 Ocak 2018 ile 31 Aralık 2021 tarihleri arasında GBS tanısı alan 121 hastanın tıbbi kayıtlarını retrospektif olarak inceledik. Demografik özellikler, başvuru şikayetleri, ek hastalıklar, geçirilmiş enfeksiyon öyküsü, nörolojik muayene bulguları, 1. gün ve 1. ay sonu GBS Disabilite Skorları (GDS), serolojik ve beyin omurilik sıvısı (BOS) incelemesi laboratuvar parametreleri, elektromiyonörografi sonuçları, GBS alt tipleri, tedaviler, tedaviye bağlı komplikasyonlar ve prognozlar kaydedildi. Bulgular 121 hastanın ortanca yaşı 58’di (20-87) (n = 73 erkek, %60). Ortalama GDS başvuruda 3 ve birinci ayın sonunda 2 idi. Serum C-reaktif protein (CRP) ve BOS protein seviyeleri yüksek, D vitamini seviyeleri düşüktü. İleri yaş, kraniyal sinir tutulumu, enfeksiyon öyküsü, yoğun bakım ünitesine (YBÜ) yatış, mekanik ventilasyon (MV) ihtiyacı, komplikasyon varlığı, yüksek plazma CRP düzeyleri, nötrofil-lenfosit oranı (NLR) ve trombosit-lenfosit oranı (PLO) GBS hastalarında 1. gün ve 1. ayın sonunda ciddi engellilik ile anlamlı şekilde ilişkiliydi. Sonuç GBS hastalarında ciddi engelliliği tahmin edebilecek çok sayıda özellik belirledik.

🔖

Cite This Article

GÖRGÜLÜ, Ü., GEÇER, B., BİLEN, Ş., KOLCU, G. (2022). EARLY PREDICTORS OF SEVERE DISABILITY IN GUILLAIN–BARRÉ SYNDROME. SDÜ Tıp Fakültesi Dergisi, Cilt: 29 - Sayı: 4, 643–649. https://ajindex.com/articles/870562

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Nobuhiro Y, Hartung HP. "Guillain–barré syndrome." New England Journal of Medicine 2012;366.24:2294-2304
  2. McGrogan A, Madle GC, Seaman HE, De Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. Neuroepidemiology 2009;32(2):150-163
  3. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011;36(2):123-133
  4. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. The Lancet, 2021;397(10280):1214-1228
  5. Hao Y, Wang W, Jacobs BC, Qiao B, Chen M, Liu D, et al. Antecedent infections in Guillain‐Barré syndrome: a single‐center, prospective study. Annals of clinical and translational neurology 2019;6(12):2510-2517
  6. Willison HJ, Yuki N. Peripheral neuropathies and anti‐glycolipid antibodies. Brain 2022;125(12):2591-2625
  7. Hafer‐Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, McKhann GM, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society 2019;39(5):625-635
  8. Malek E, Salameh J. Guillain–Barre Syndrome. In Seminars in neurology 2019;39:589-595
  9. Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. Journal of Neurology, Neurosurgery & Psychiatry 2013;84(5): 576-583
  10. Rajabally YA, Durand MC, Mitchell J, Orlikowski D, Nicolas G. Electrophysiological diagnosis of Guillain–Barré syndrome subtype: could a single study suffice? Journal of Neurology, Neurosurgery & Psychiatry 2015;86(1):115-119
  11. Restrepo-Jiménez P, Rodríguez Y, González P, et al. The immunotherapy of Guillain-Barré syndrome. Expert Opin Biol Ther 2018;18(6):619-631. doi: 10.1080/14712598.2018. 1468885
  12. Rajabally YA, Uncini A. Outcome and its predictors in Guillain– Barré syndrome. Journal of Neurology, Neurosurgery & Psychiatry 2012;83(7):711-718
  13. Walgaard C, Lingsma HF, Ruts L, Van Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain- Barre syndrome. Neurology 2011;76(11):968-975 14. Verma R, Chaudhari TS, Raut TP, Garg RK. Clinico-electrophysiological profile and predictors of functional outcome in Guillain–Barre syndrome (GBS). Journal of the neurological sciences 2013;335(1-2):105-111
  14. Tunç A. Early predictors of functional disability in Guillain–Barré Syndrome. Acta Neurologica Belgica 2019;119(4):555-559.